Fig. 7.
Change in the domains of the Work Productivity and Activity Impairment Questionnaire for Psoriasis (WPAI:PsO) Impairment for patients with psoriasis treated with ixekizumab (IXE) or ustekinumab (UST) for 52 weeks including (A) Absenteeism, (B) Presenteeism, (C) Work Productivity Loss, and (D) Activity Impairment. mBOCF: modified baseline-observation carried forward.
